News

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...
“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...
Discover how Semaglutide helped me lose 120 pounds and transform my life. A personal, honest look at the ups, downs, and what really worked.
Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.
In 2025, the discourse surrounding prescription weight loss treatments is gaining momentum, fueled by increasing public awareness of GLP-1 receptor agonists, such as semaglutide and tirzepatide.
Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...
In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...
Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...